AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SSR Mining

Bargains abound, even with the stock market a stone's throw from a new high.

Got $1,500? These Surefire Stocks Are Begging to Be Bought

Boeing

Want to start investing but afraid you don't have enough money?

6 Ways to Start Investing With $100 or Less

Daiichi Sankyo Co Ltd

Roche Holding AG

AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3 trial of Enhertu. The trial reached its primary endpoint in a study including HER2-positive metastatic breast cancer patients who had previously been treated with one prior line of HER2-based therapy.

AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer

The European Union has approved AstraZeneca plc's (NASDAQ: AZN) Forxiga (dapagliflozin) for chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). Forxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.

AstraZeneca's Forxiga Wins European Approval For Chronic Kidney Disease

AstraZeneca PLC (LSE:AZN) offers sector-leading diversified growth at a reasonable price, according to Morgan Stanley (NYSE:MS). The investment bank resumed coverage with an ‘overweight' recommendation and a 9,800p target price, adding that risks are “skewed to the upside given growth and significant pipeline & product optionality”.

AstraZeneca offers sector-leading growth at reasonable price, says Morgan Stanley

AstraZeneca PLC (LSE:AZN) (LSE:AZN) announced that Forxiga has been approved in the EU for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes. CKD is a serious, progressive condition defined by decreased kidney function and is often associated with an increased risk of heart disease or stroke.

AstraZeneca receives EU approval for chronic kidney disease drug

Sierra Oncology

Sierra Oncology Inc (NASDAQ: SRRA) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ: AZN) for AZD5153, a potent, and selective BRD4 BET inhibitor with a novel bivalent binding mode.  Sierra plans to initiate a Phase 2 study evaluating momelotinib in combination with AZD5153 in myelofibrosis patients in 1H of 2022.

Sierra Oncology Bets $216M On AstraZeneca's BET Inhibitor For Myelofibrosis

GlaxoSmithKline

Under-fire boss of GlaxoSmithKline PLC, Emma Walmsley, has received support from an unlikely source: Pascal Soriot, the boss of rival pharma giant AstraZeneca PLC. In an interview with The Daily Mail, Soriot advised Walmsley to stick to her guns and implement her business plan.

AstraZeneca boss urges rival at GlaxoSmithKline to stick to her guns

AstraZeneca PLC boss urges rival at GlaxoSmithKline to stick to her guns

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (LSE/STO/NASDAQ: AZN) for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in

Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline

The FDA recently approved Ultomiris as a treatment for paroxysmal nocturnal hemoglobinuria patients who are under 18, and it should get a similar label expansion in the E.U. soon.

Can Ultomiris Continue to Drive Growth for AstraZeneca?

Johnson & Johnson

Moderna

Pfizer

It'll push the winners further ahead of the laggards.

How the Delta Variant Could Change the World of Coronavirus Vaccine Stocks

Yamana Gold

General Motors

3 Value Stocks That'll Make You Richer in August (and Beyond)

Combining AstraZeneca plc's (NASDAQ: AZN) COVID-19 vaccine with a second dose from either Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) or Moderna Inc's (NASDAQ: MRNA) shot provides "good protection," Denmark's State Serum Institute (SSI) said. More than 144,000 Danish citizens, mostly healthcare frontline personnel and the elderly, received their first jab from AstraZeneca and subsequent shot from either Pfizer-BioNTech or Moderna, reports Reuters.

Combining AstraZeneca, mRNA COVID-19 Vaccines Show Efficacy In Danish Study: Reuters

The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) Saphnelo (anifrolumab-fnia) for adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. SLE is an autoimmune disease in which the immune system attacks healthy tissue in the body.

AstraZeneca' Saphnelo Wins FDA Nod For Systemic Lupus Erythematosus, Marking New Treatment Approval In 10 Years

The reported new contracts come as experts mull booster shots to combat the fast-spreading Delta coronavirus variant.

Pfizer and Moderna hiked their COVID-19 vaccine prices in the EU after AstraZeneca lost popularity there, report says

AstraZeneca PLC announced that Saphnelo has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. SLE is the most common form of lupus affecting up to 300,000 people in the US, disproportionately affects the African-American, Hispanic and Asian populations.

AstraZeneca receives US approval for lupus drug Saphnelo

AstraZeneca PLC (AZN) CEO Pascal Soriot on Q2 2021 Results - Earnings Call Transcript

The new approval to treat a form of lung cancer will be pivotal to dominating a massive market.

This Drug's New Indication in China Will Be a Boost to AstraZeneca

Today AstraZeneca plc (NASDAQ: AZN) released its second-quarter earnings with updated sales numbers for its COVID-19 vaccine; when compared to the big mRNA players, the numbers looked rather pale. Q2 Sales Numbers: AstraZeneca's COVID-19 jab clocked in about $1.17 billion globally in the first half, including $894 million in the second quarter alone.

Cashing COVID-19 Vaccine - AstraZeneca Or Pfizer

McDonald's

Microsoft

Walmart

Low-beta stocks can protect a portfolio from a market correction. These four stocks have low volatility and high dividend yields.

4 Low Beta Stocks to Protect Your Portfolio Against Any Correction

AstraZeneca (AZN) surpasses second-quarter estimates for revenues while earnings meet estimates. Stock up in pre-market.

AstraZeneca (AZN) Q2 Earnings In Line, Vaccine Aids Sales

AstraZeneca PLC has started to question its long-term role in Covid-19 vaccines and will make a decision on its involvement by the end of the year, according to a senior executive. The pharma has been one of the Covid-19 heroes, working in partnership with Oxford University to help develop and distribute a vaccine for the virus in record time even though it had little experience beforehand.

AstraZeneca questioning future Covid-19 vaccine involvement

The company previously indicated it would pursue an emergency use authorization but has struggled to meet the U.S. regulator's demand for data.

AstraZeneca Eyes Full U.S. Approval For Covid Shot This Year, Skipping Faster Emergency Authorization

AstraZeneca plc (NASDAQ: AZN) is reportedly exploring its options for the future of its COVID-19 vaccine business. The Company expects clarity on the matter by the end of 2021.

AstraZeneca Looking At Potential Options for COVID-19 Vaccine Business: Reuters

News for AstraZeneca Stock (AZN)